EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition.

Summary: Imagine having a lock on a door that needs two specific keys to open. In a small group of breast cancer patients (about 1 to 5 out of 100), their cancer cells have two specific changes, called EGFR and PI3K. These changes make the cancer grow faster and harder to treat. Scientists tested a new idea: using two medicines at the same time to block both of these changes. It worked! By using both "keys" together, they successfully stopped the cancer cells from growing, caused the bad cells to die off, and shrank tumors in lab tests. This double-team approach is a very promising treatment for this specific type of breast cancer.